Clinical trial of HIV vaccine demonstrates 90 percent difference

According to research by Seek, a privately owned British biopharmaceutical company,  a clinical trial of an HIV vaccine demonstrates an approximately 90 percent difference in HIV-infected people.
Gregory Stoloff, the chief executive officer of Seek, said that this is the first time that a human immunodeficiency virus vaccine has shown such a meaningful result in a human clinical trial, reports UPI.
"The next step will be to progress this to final human trials and determine the optimum dose and dosing regime to further enhance the vaccine's efficacy," Stoloff said in a statement, according to UPI.
Seek's HIV-v vaccine targets the conserved regions in the internal proteins of the HIV virus that remain constant across all HIV strains. The development of an effective vaccine against HIV has been difficult due to the constant mutation of the virus.
Stoloff said that the vaccine is the first to generate both strong T-cell and antibody responses to eliminate HIV-infected cells and neutralize the HIV virus, UPI reports. The HIV-v vaccine primes the immune system to recognize and target the regions within HIV proteins that are present in all recorded strains of the virus.
Officials at Seek say that there will be therapeutic Phase III trials in 2012-2013, when it will begin recruiting HIV-infected patients whose viral-level loads will be monitored to determine the optimal dose and dosing regime. If approved, the vaccine could be available to patients in three to five years.